drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00227 | DB12015 | 1,463 | 1,033 | [
"DDInter1098",
"DDInter53"
] | Lovastatin | Alpelisib | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1463,
24,
1033
]
],
[
[
1463,
24,
951
],
[
951,
24,
1033
]
],
[
[
1463,
25,
1510
],
[
1510,
24,
1033
]
],
[
[
1463,
63,
837
],
[
837,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
... | Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Lovastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may... |
DB01128 | DB08865 | 918 | 1,593 | [
"DDInter204",
"DDInter448"
] | Bicalutamide | Crizotinib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
918,
25,
1593
]
],
[
[
918,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
918,
7,
17537
],
[
17537,
46,
1593
]
],
[
[
918,
18,
16974
],
[
16974... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cri... | Bicalutamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Bicalutamide (Compound) upregulates USP6NL (Gene) and USP6NL (Gene) is upregulated by Crizotinib (Compound)
Bicalutamide (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Crizotinib (Compound)
Bicalu... |
DB00789 | DB09237 | 1,431 | 1,586 | [
"DDInter796",
"DDInter1045"
] | Gadopentetic acid | Levamlodipine | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1431,
24,
1586
]
],
[
[
1431,
24,
1013
],
[
1013,
63,
1586
]
],
[
[
1431,
24,
512
],
[
512,
24,
1586
]
],
[
[
1431,
24,
1013
],
[
1013... | [
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tyropanoic... | Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken... |
DB00087 | DB06168 | 599 | 1,531 | [
"DDInter41",
"DDInter281"
] | Alemtuzumab | Canakinumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
599,
24,
1531
]
],
[
[
599,
24,
1644
],
[
1644,
24,
1531
]
],
[
[
599,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
599,
63,
541
],
[
541,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaratumab"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Olaratumab and Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purifie... |
DB00912 | DB01208 | 473 | 945 | [
"DDInter1581",
"DDInter1705"
] | Repaglinide | Sparfloxacin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Major | 2 | [
[
[
473,
25,
945
]
],
[
[
473,
25,
739
],
[
739,
1,
945
]
],
[
[
473,
64,
1176
],
[
1176,
1,
945
]
],
[
[
473,
21,
28787
],
[
28787,
... | [
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Repaglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
... | Repaglinide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Repaglinide may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Compound)
Repaglinide (Com... |
DB00804 | DB00836 | 1,507 | 543 | [
"DDInter543",
"DDInter1088"
] | Dicyclomine | Loperamide | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
1507,
24,
543
]
],
[
[
1507,
24,
704
],
[
704,
40,
543
]
],
[
[
1507,
63,
675
],
[
675,
24,
543
]
],
[
[
1507,
21,
28722
],
[
28722,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Loperamide (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interact... |
DB00334 | DB00748 | 867 | 662 | [
"DDInter1326",
"DDInter297"
] | Olanzapine | Carbinoxamine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
867,
24,
662
]
],
[
[
867,
24,
1594
],
[
1594,
24,
662
]
],
[
[
867,
6,
6017
],
[
6017,
45,
662
]
],
[
[
867,
24,
1429
],
[
1429,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Olanzapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Olanzapine m... |
DB01159 | DB12267 | 419 | 1,476 | [
"DDInter854",
"DDInter233"
] | Halothane | Brigatinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
419,
24,
1476
]
],
[
[
419,
63,
629
],
[
629,
24,
1476
]
],
[
[
419,
24,
1250
],
[
1250,
24,
1476
]
],
[
[
419,
25,
478
],
[
478,
... | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib m... |
DB00691 | DB01240 | 1,058 | 885 | [
"DDInter1237",
"DDInter657"
] | Moexipril | Epoprostenol | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1058,
24,
885
]
],
[
[
1058,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1058,
63,
1512
],
[
1512,
24,
885
]
],
[
[
1058,
1,
664
],
[
664,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that c... |
DB00722 | DB01097 | 743 | 1,377 | [
"DDInter1079",
"DDInter1033"
] | Lisinopril | Leflunomide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
743,
25,
1377
]
],
[
[
743,
5,
11573
],
[
11573,
44,
1377
]
],
[
[
743,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
743,
24,
959
],
[
959,... | [
[
[
"Lisinopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Lisinopril",
"{u} (Compound) treats {v} (Disease)",
"systemic scleroderma"
],
[
"systemic scleroderma",
"{u} (Disease) is trea... | Lisinopril (Compound) treats systemic scleroderma (Disease) and systemic scleroderma (Disease) is treated by Leflunomide (Compound)
Lisinopril (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Lisinopril may cause a moderate interaction that could exacerbate d... |
DB11581 | DB11828 | 1,456 | 1,406 | [
"DDInter1926",
"DDInter1281"
] | Venetoclax | Neratinib | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
1456,
24,
1406
]
],
[
[
1456,
62,
1135
],
[
1135,
23,
1406
]
],
[
[
1456,
64,
392
],
[
392,
24,
1406
]
],
[
[
1456,
63,
1252
],
[
1252... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Venetoclax",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Venetoclax may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderat... |
DB00696 | DB01110 | 826 | 86 | [
"DDInter665",
"DDInter1209"
] | Ergotamine | Miconazole | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
826,
24,
86
]
],
[
[
826,
6,
4973
],
[
4973,
45,
86
]
],
[
[
826,
21,
28722
],
[
28722,
60,
86
]
],
[
[
826,
25,
222
],
[
222,
2... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Ergotamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Ergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Miconazole (Compound)
Ergotamine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Miconazole (Compound)
Ergotamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a mi... |
DB00393 | DB12130 | 854 | 1,017 | [
"DDInter1295",
"DDInter1094"
] | Nimodipine | Lorlatinib | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
854,
24,
1017
]
],
[
[
854,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
854,
1,
409
],
[
409,
24,
1017
]
],
[
[
854,
24,
1446
],
[
1446,
... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Nimodipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could e... |
DB00397 | DB00502 | 1,466 | 1,300 | [
"DDInter1458",
"DDInter853"
] | Phenylpropanolamine | Haloperidol | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Moderate | 1 | [
[
[
1466,
24,
1300
]
],
[
[
1466,
6,
4886
],
[
4886,
45,
1300
]
],
[
[
1466,
18,
2183
],
[
2183,
57,
1300
]
],
[
[
1466,
21,
28929
],
[
28... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Haloperidol"
]
],
[
[
"Phenylpropanolamine",
"{u} (Compound) binds {v} (Gene)",
"DRD1"
],
[
"DRD1",
"{u} (Gene) is bound by {... | Phenylpropanolamine (Compound) binds DRD1 (Gene) and DRD1 (Gene) is bound by Haloperidol (Compound)
Phenylpropanolamine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Haloperidol (Compound)
Phenylpropanolamine (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effe... |
DB00682 | DB01021 | 126 | 674 | [
"DDInter1951",
"DDInter1861"
] | Warfarin | Trichlormethiazide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Minor | 0 | [
[
[
126,
23,
674
]
],
[
[
126,
62,
1014
],
[
1014,
40,
674
]
],
[
[
126,
23,
178
],
[
178,
1,
674
]
],
[
[
126,
23,
359
],
[
359,
40... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Benzthiazide"
],
[
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Trichlormethia... |
DB01064 | DB09564 | 1,148 | 1,296 | [
"DDInter987",
"DDInter930"
] | Isoprenaline | Insulin degludec | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1148,
24,
1296
]
],
[
[
1148,
74,
17
],
[
17,
24,
1296
]
],
[
[
1148,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1148,
63,
1645
],
[
1645,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Isoprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases wh... | Isoprenaline (Compound) resembles Sotalol (Compound) and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Isoprenaline may cause a moderate interaction that co... |
DB00059 | DB00624 | 1,560 | 1,561 | [
"DDInter1404",
"DDInter1775"
] | Pegaspargase | Testosterone | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Moderate | 1 | [
[
[
1560,
24,
1561
]
],
[
[
1560,
24,
155
],
[
155,
1,
1561
]
],
[
[
1560,
24,
1026
],
[
1026,
40,
1561
]
],
[
[
1560,
24,
891
],
[
891,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxymesterone"
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Testosterone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Test... |
DB00635 | DB00814 | 1,573 | 1,171 | [
"DDInter1515",
"DDInter1143"
] | Prednisone | Meloxicam | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
1573,
24,
1171
]
],
[
[
1573,
63,
1027
],
[
1027,
40,
1171
]
],
[
[
1573,
6,
8374
],
[
8374,
45,
1171
]
],
[
[
1573,
5,
11653
],
[
116... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Meloxicam (Compound)
Prednisone (Compound) treats systemic lupus erythematosus (Disease) an... |
DB00379 | DB09065 | 143 | 760 | [
"DDInter1206",
"DDInter424"
] | Mexiletine | Cobicistat | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
143,
24,
760
]
],
[
[
143,
24,
1374
],
[
1374,
23,
760
]
],
[
[
143,
24,
868
],
[
868,
24,
760
]
],
[
[
143,
63,
608
],
[
608,
2... | [
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemur... |
DB00948 | DB09420 | 1,681 | 1,074 | [
"DDInter1207",
"DDInter953"
] | Mezlocillin | Iodide I-123 | Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections. | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Moderate | 1 | [
[
[
1681,
24,
1074
]
],
[
[
1681,
40,
339
],
[
339,
24,
1074
]
],
[
[
1681,
63,
126
],
[
126,
24,
1074
]
],
[
[
1681,
40,
339
],
[
339,
... | [
[
[
"Mezlocillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-123"
]
],
[
[
"Mezlocillin",
"{u} (Compound) resembles {v} (Compound)",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} may cause... | Mezlocillin (Compound) resembles Bacampicillin (Compound) and Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123
Mezlocillin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that... |
DB00836 | DB01148 | 543 | 1,128 | [
"DDInter1088",
"DDInter738"
] | Loperamide | Flavoxate | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Moderate | 1 | [
[
[
543,
24,
1128
]
],
[
[
543,
1,
11264
],
[
11264,
40,
1128
]
],
[
[
543,
7,
5833
],
[
5833,
57,
1128
]
],
[
[
543,
21,
28762
],
[
28762... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flavoxate"
]
],
[
[
"Loperamide",
"{u} (Compound) resembles {v} (Compound)",
"Diphenidol"
],
[
"Diphenidol",
"{u} (Compound) resembles... | Loperamide (Compound) resembles Diphenidol (Compound) and Diphenidol (Compound) resembles Flavoxate (Compound)
Loperamide (Compound) upregulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Flavoxate (Compound)
Loperamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Flavoxate (C... |
DB00008 | DB00019 | 491 | 1,257 | [
"DDInter1407",
"DDInter1405"
] | Peginterferon alfa-2a | Pegfilgrastim | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Moderate | 1 | [
[
[
491,
24,
1257
]
],
[
[
491,
24,
919
],
[
919,
63,
1257
]
],
[
[
491,
25,
1101
],
[
1101,
63,
1257
]
],
[
[
491,
24,
1451
],
[
1451,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pe... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Pegvaliase and Pegvaliase may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Bexarotene ... |
DB00476 | DB00585 | 109 | 1,127 | [
"DDInter608",
"DDInter1309"
] | Duloxetine | Nizatidine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Minor | 0 | [
[
[
109,
23,
1127
]
],
[
[
109,
23,
1194
],
[
1194,
40,
1127
]
],
[
[
109,
18,
10182
],
[
10182,
57,
1127
]
],
[
[
109,
21,
28898
],
[
288... | [
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nizatidine"
]
],
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
... | Duloxetine may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine (Compound) resembles Nizatidine (Compound)
Duloxetine (Compound) downregulates CDCA4 (Gene) and CDCA4 (Gene) is downregulated by Nizatidine (Compound)
Duloxetine (Compound) causes Constipation (Side Effect... |
DB00445 | DB08916 | 322 | 26 | [
"DDInter655",
"DDInter32"
] | Epirubicin | Afatinib | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal grow... | Moderate | 1 | [
[
[
322,
24,
26
]
],
[
[
322,
63,
883
],
[
883,
40,
26
]
],
[
[
322,
7,
14278
],
[
14278,
45,
26
]
],
[
[
322,
18,
3573
],
[
3573,
4... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Afatinib (Compound)
Epirubicin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Afatinib (Compound)
Epirubicin (Compound) downregulates DYRK1A (Gene) and DYRK1A (Gene) ... |
DB00783 | DB11827 | 1,438 | 433 | [
"DDInter679",
"DDInter669"
] | Estradiol | Ertugliflozin | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
1438,
24,
433
]
],
[
[
1438,
24,
959
],
[
959,
24,
433
]
],
[
[
1438,
63,
251
],
[
251,
24,
433
]
],
[
[
1438,
1,
35
],
[
35,
24... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Beta... |
DB00640 | DB12332 | 1,585 | 1,619 | [
"DDInter31",
"DDInter1626"
] | Adenosine | Rucaparib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1585,
24,
1619
]
],
[
[
1585,
24,
888
],
[
888,
24,
1619
]
],
[
[
1585,
64,
1181
],
[
1181,
24,
1619
]
],
[
[
1585,
63,
1031
],
[
1031... | [
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
... | Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Adenosine may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a m... |
DB08868 | DB13074 | 1,011 | 877 | [
"DDInter737",
"DDInter1110"
] | Fingolimod | Macimorelin | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1011,
25,
877
]
],
[
[
1011,
62,
112
],
[
112,
23,
877
]
],
[
[
1011,
63,
673
],
[
673,
24,
877
]
],
[
[
1011,
25,
913
],
[
913,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Fingolimod may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and A... |
DB00092 | DB00294 | 58 | 1,336 | [
"DDInter40",
"DDInter701"
] | Alefacept | Etonogestrel | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
58,
24,
1336
]
],
[
[
58,
24,
566
],
[
566,
1,
1336
]
],
[
[
58,
24,
873
],
[
873,
40,
1336
]
],
[
[
58,
63,
581
],
[
581,
24,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Norgestimate and Norgestimate (Compound) resembles Etonogestr... |
DB00342 | DB09083 | 1,181 | 880 | [
"DDInter1770",
"DDInter996"
] | Terfenadine | Ivabradine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1181,
25,
880
]
],
[
[
1181,
24,
480
],
[
480,
24,
880
]
],
[
[
1181,
24,
159
],
[
159,
63,
880
]
],
[
[
1181,
25,
752
],
[
752,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoter... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and L... |
DB00563 | DB00855 | 663 | 213 | [
"DDInter1174",
"DDInter72"
] | Methotrexate | Aminolevulinic acid | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
663,
25,
213
]
],
[
[
663,
7,
18134
],
[
18134,
46,
213
]
],
[
[
663,
18,
8355
],
[
8355,
57,
213
]
],
[
[
663,
7,
2389
],
[
2389,
... | [
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Methotrexate",
"{u} (Compound) upregulates {v} (Gene)",
"POLD4"
],
[
"POLD4",
"{u} (Gene) is upregulated by {v} (Com... | Methotrexate (Compound) upregulates POLD4 (Gene) and POLD4 (Gene) is upregulated by Aminolevulinic acid (Compound)
Methotrexate (Compound) downregulates DPH2 (Gene) and DPH2 (Gene) is downregulated by Aminolevulinic acid (Compound)
Methotrexate (Compound) upregulates CCDC85B (Gene) and CCDC85B (Gene) is downregulated b... |
DB00242 | DB06212 | 1,064 | 165 | [
"DDInter392",
"DDInter1833"
] | Cladribine | Tolvaptan | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
1064,
24,
165
]
],
[
[
1064,
21,
28981
],
[
28981,
60,
165
]
],
[
[
1064,
24,
466
],
[
466,
62,
165
]
],
[
[
1064,
25,
594
],
[
594,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Cladribine",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Ef... | Cladribine (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Tolvaptan (Compound)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when tak... |
DB00031 | DB00374 | 20 | 1,061 | [
"DDInter1764",
"DDInter1852"
] | Tenecteplase | Treprostinil | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Moderate | 1 | [
[
[
20,
24,
1061
]
],
[
[
20,
24,
885
],
[
885,
40,
1061
]
],
[
[
20,
23,
539
],
[
539,
62,
1061
]
],
[
[
20,
24,
914
],
[
914,
63,
... | [
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
]
],
[
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) resembles Treprostinil (Compound)
Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can ... |
DB00757 | DB01059 | 1,166 | 956 | [
"DDInter581",
"DDInter1313"
] | Dolasetron | Norfloxacin | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Major | 2 | [
[
[
1166,
25,
956
]
],
[
[
1166,
25,
872
],
[
872,
40,
956
]
],
[
[
1166,
64,
1176
],
[
1176,
1,
956
]
],
[
[
1166,
25,
1539
],
[
1539,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"... | Dolasetron may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Dolasetron may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Dolasetron may lead ... |
DB01075 | DB09117 | 1,376 | 957 | [
"DDInter569",
"DDInter1391"
] | Diphenhydramine | Paraldehyde | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
1376,
24,
957
]
],
[
[
1376,
40,
126
],
[
126,
23,
957
]
],
[
[
1376,
35,
1264
],
[
1264,
24,
957
]
],
[
[
1376,
63,
1648
],
[
1648,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a ... | Diphenhydramine (Compound) resembles Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Paraldehyde
Diphenhydramine (Compound) resembles Doxepin (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Doxe... |
DB11921 | DB15093 | 1,019 | 1,654 | [
"DDInter492",
"DDInter1698"
] | Deflazacort | Somapacitan | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1019,
24,
1654
]
],
[
[
1019,
63,
433
],
[
433,
24,
1654
]
],
[
[
1019,
64,
351
],
[
351,
24,
1654
]
],
[
[
1019,
24,
159
],
[
159,
... | [
[
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
... | Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Deflazacort may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib m... |
DB01364 | DB09082 | 22 | 659 | [
"DDInter650",
"DDInter1934"
] | Ephedrine | Vilanterol | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
22,
24,
659
]
],
[
[
22,
62,
1220
],
[
1220,
23,
659
]
],
[
[
22,
63,
895
],
[
895,
24,
659
]
],
[
[
22,
24,
1296
],
[
1296,
63,... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Ephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
... | Ephedrine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and M... |
DB01124 | DB01294 | 1,411 | 266 | [
"DDInter1828",
"DDInter215"
] | Tolbutamide | Bismuth subsalicylate | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of [salicylic acid] linked to trivalent [bismuth cation]. Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. Bismuth s... | Moderate | 1 | [
[
[
1411,
24,
266
]
],
[
[
1411,
21,
28829
],
[
28829,
60,
266
]
],
[
[
1411,
62,
1347
],
[
1347,
24,
266
]
],
[
[
1411,
24,
1254
],
[
125... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
]
],
[
[
"Tolbutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Hyponatraemia"
],
[
"Hyponatraemia",
"{u} ... | Tolbutamide (Compound) causes Hyponatraemia (Side Effect) and Hyponatraemia (Side Effect) is caused by Bismuth subsalicylate (Compound)
Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases wh... |
DB00283 | DB01173 | 701 | 358 | [
"DDInter395",
"DDInter1349"
] | Clemastine | Orphenadrine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
701,
24,
358
]
],
[
[
701,
24,
211
],
[
211,
1,
358
]
],
[
[
701,
1,
11268
],
[
11268,
1,
358
]
],
[
[
701,
24,
272
],
[
272,
24... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Clemastine (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Orphenadrine (Compound)
Clemastine may cause a moderate intera... |
DB09078 | DB11967 | 1,228 | 710 | [
"DDInter1036",
"DDInter210"
] | Lenvatinib | Binimetinib | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1228,
24,
710
]
],
[
[
1228,
24,
1293
],
[
1293,
24,
710
]
],
[
[
1228,
64,
1593
],
[
1593,
24,
710
]
],
[
[
1228,
63,
1237
],
[
1237,... | [
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
],
[
... | Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine and Valbenazine may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Lenvatinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cau... |
DB00668 | DB06203 | 874 | 1,002 | [
"DDInter652",
"DDInter51"
] | Epinephrine | Alogliptin | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
874,
24,
1002
]
],
[
[
874,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
874,
6,
8374
],
[
8374,
45,
1002
]
],
[
[
874,
21,
29222
],
[
29222,... | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[... | Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Epinephrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Alogliptin (Compound)
Epinephrine (Compound) causes Hypoglycaemia (Side Effect) and ... |
DB00682 | DB00731 | 126 | 1,144 | [
"DDInter1951",
"DDInter1269"
] | Warfarin | Nateglinide | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
126,
24,
1144
]
],
[
[
126,
62,
168
],
[
168,
24,
1144
]
],
[
[
126,
6,
6943
],
[
6943,
45,
1144
]
],
[
[
126,
25,
804
],
[
804,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Warfarin (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Nateglinide (Compound)
Warfarin may lead to a maj... |
DB00247 | DB01234 | 1,131 | 1,220 | [
"DDInter1194",
"DDInter513"
] | Methysergide | Dexamethasone | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1131,
24,
1220
]
],
[
[
1131,
18,
5901
],
[
5901,
57,
1220
]
],
[
[
1131,
21,
28769
],
[
28769,
60,
1220
]
],
[
[
1131,
25,
22
],
[
22... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Methysergide",
"{u} (Compound) downregulates {v} (Gene)",
"GJA1"
],
[
"GJA1",
"{u} (Gene) is downregulated ... | Methysergide (Compound) downregulates GJA1 (Gene) and GJA1 (Gene) is downregulated by Dexamethasone (Compound)
Methysergide (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Dexamethasone (Compound)
Methysergide may lead to a major life threatening interaction when taken w... |
DB00072 | DB00087 | 550 | 599 | [
"DDInter1846",
"DDInter41"
] | Trastuzumab | Alemtuzumab | Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth ... | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Moderate | 1 | [
[
[
550,
24,
599
]
],
[
[
550,
24,
597
],
[
597,
63,
599
]
],
[
[
550,
63,
1184
],
[
1184,
24,
599
]
],
[
[
550,
25,
77
],
[
77,
63,... | [
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
]
],
[
[
"Trastuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra... |
DB00418 | DB01284 | 536 | 1,042 | [
"DDInter1650",
"DDInter1782"
] | Secobarbital | Tetracosactide | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
536,
24,
1042
]
],
[
[
536,
40,
1023
],
[
1023,
24,
1042
]
],
[
[
536,
24,
761
],
[
761,
63,
1042
]
],
[
[
536,
25,
126
],
[
126,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may c... | Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate intera... |
DB00539 | DB11901 | 11 | 913 | [
"DDInter1837",
"DDInter107"
] | Toremifene | Apalutamide | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
11,
25,
913
]
],
[
[
11,
23,
112
],
[
112,
23,
913
]
],
[
[
11,
24,
279
],
[
279,
24,
913
]
],
[
[
11,
64,
600
],
[
600,
24,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and An... |
DB01001 | DB14881 | 688 | 180 | [
"DDInter1632",
"DDInter1329"
] | Salbutamol | Oliceridine | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
688,
24,
180
]
],
[
[
688,
62,
112
],
[
112,
23,
180
]
],
[
[
688,
24,
401
],
[
401,
24,
180
]
],
[
[
688,
63,
618
],
[
618,
24,... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and P... |
DB01142 | DB01579 | 1,264 | 341 | [
"DDInter593",
"DDInter1439"
] | Doxepin | Phendimetrazine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
1264,
24,
341
]
],
[
[
1264,
63,
499
],
[
499,
1,
341
]
],
[
[
1264,
6,
5214
],
[
5214,
45,
341
]
],
[
[
1264,
21,
28662
],
[
28662,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phensuximide"
],
[
... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Phendimetrazine (Compound)
Doxepin (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Phendimetrazine (Compound)
Doxepin (Compound) causes Tremor (Side Effect) and Tremor ... |
DB00502 | DB09330 | 1,300 | 985 | [
"DDInter853",
"DDInter1352"
] | Haloperidol | Osimertinib | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
1300,
25,
985
]
],
[
[
1300,
23,
112
],
[
112,
23,
985
]
],
[
[
1300,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1300,
23,
663
],
[
663,
... | [
[
[
"Haloperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Haloperidol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Haloperidol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Iv... |
DB00250 | DB01032 | 10 | 824 | [
"DDInter475",
"DDInter1522"
] | Dapsone | Probenecid | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy. | Moderate | 1 | [
[
[
10,
24,
824
]
],
[
[
10,
1,
11259
],
[
11259,
1,
824
]
],
[
[
10,
6,
8374
],
[
8374,
45,
824
]
],
[
[
10,
21,
29554
],
[
29554,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound)",
"Sulfacetamide"
],
[
"Sulfacetamide",
"{u} (Compound) resemble... | Dapsone (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Probenecid (Compound)
Dapsone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Probenecid (Compound)
Dapsone (Compound) causes Nephrotic syndrome (Side Effect) and Nephrotic syndrome (Side Effect) is caused by Probe... |
DB00371 | DB00835 | 1,050 | 100 | [
"DDInter1154",
"DDInter245"
] | Meprobamate | Brompheniramine | A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1050,
24,
100
]
],
[
[
1050,
24,
832
],
[
832,
24,
100
]
],
[
[
1050,
24,
649
],
[
649,
63,
100
]
],
[
[
1050,
63,
1594
],
[
1594,
... | [
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Meprobamate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
... | Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Meprobamate may cause a moderate interaction that could exacerbate diseases when taken with Clofed... |
DB00630 | DB01377 | 1,485 | 1,283 | [
"DDInter42",
"DDInter1119"
] | Alendronic acid | Magnesium oxide | Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Moderate | 1 | [
[
[
1485,
24,
1283
]
],
[
[
1485,
23,
1194
],
[
1194,
23,
1283
]
],
[
[
1485,
62,
752
],
[
752,
23,
1283
]
],
[
[
1485,
24,
1479
],
[
1479... | [
[
[
"Alendronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Alendronic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
... | Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Alendronic acid may cause a minor interaction that can limit clinical effects when taken with Cimetidine a... |
DB00026 | DB15965 | 1,184 | 1,330 | [
"DDInter94",
"DDInter1270"
] | Anakinra | Naxitamab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
1184,
24,
1330
]
],
[
[
1184,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
1184,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
1184,
25,
980
],
[
980... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfam... |
DB00254 | DB00459 | 964 | 640 | [
"DDInter598",
"DDInter21"
] | Doxycycline | Acitretin | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of etretinate with the advantage of a much shorter half-life when compared with etretinate. | Major | 2 | [
[
[
964,
25,
640
]
],
[
[
964,
25,
1517
],
[
1517,
64,
640
]
],
[
[
964,
24,
637
],
[
637,
63,
640
]
],
[
[
964,
63,
305
],
[
305,
2... | [
[
[
"Doxycycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
]
],
[
[
"Doxycycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"... | Doxycycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Acitretin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi and Asparagi... |
DB00377 | DB01263 | 1,494 | 859 | [
"DDInter1382",
"DDInter1494"
] | Palonosetron | Posaconazole | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1494,
24,
859
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1494,
21,
28762
],
[
28762,
60,
859
]
],
[
[
1494,
23,
112
],
[
112,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Palonosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Palonosetron (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00877 | DB14881 | 629 | 180 | [
"DDInter1678",
"DDInter1329"
] | Sirolimus | Oliceridine | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
629,
24,
180
]
],
[
[
629,
24,
1094
],
[
1094,
24,
180
]
],
[
[
629,
63,
1184
],
[
1184,
24,
180
]
],
[
[
629,
25,
375
],
[
375,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinr... |
DB00512 | DB00994 | 91 | 361 | [
"DDInter1916",
"DDInter1277"
] | Vancomycin | Neomycin | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of _Streptomyces fradiae_. Neomycin is a complex comprised of three components, neomycin A, B, and C. Neomycin B, also known as [framycetin], is the most active component of the complex and neomycin C is the isomer o... | Moderate | 1 | [
[
[
91,
24,
361
]
],
[
[
91,
21,
28722
],
[
28722,
60,
361
]
],
[
[
91,
24,
1132
],
[
1132,
24,
361
]
],
[
[
91,
24,
242
],
[
242,
6... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neomycin"
]
],
[
[
"Vancomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v... | Vancomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Neomycin (Compound)
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Neomycin
Vancom... |
DB08864 | DB14568 | 786 | 982 | [
"DDInter1595",
"DDInter1000"
] | Rilpivirine | Ivosidenib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
786,
25,
982
]
],
[
[
786,
62,
112
],
[
112,
23,
982
]
],
[
[
786,
63,
1101
],
[
1101,
23,
982
]
],
[
[
786,
63,
543
],
[
543,
2... | [
[
[
"Rilpivirine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Rilpivirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Be... |
DB00963 | DB08890 | 1,263 | 16 | [
"DDInter241",
"DDInter1069"
] | Bromfenac | Linaclotide | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Linaclotide is a synthetic 14-amino acid cyclic peptide and first-in-class guanylate cyclase-C (G-CC) agonist.[A260271, L47211] Linaclotide is structurally related to human guanylin and uroguanylin, paracrine peptide hormones that are endogenous activators of GC-C. It is also a homolog of a heat-stable enterotoxin deri... | Minor | 0 | [
[
[
1263,
23,
16
]
],
[
[
1263,
63,
1314
],
[
1314,
40,
16
]
],
[
[
1263,
1,
831
],
[
831,
23,
16
]
],
[
[
1263,
63,
1512
],
[
1512,
... | [
[
[
"Bromfenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin (Compound) resembles Linaclotide (Compound)
Bromfenac (Compound) resembles Indomethacin (Compound) and Indomethacin may cause a minor interaction that can limit clinical effects when taken with Linacl... |
DB00574 | DB01050 | 121 | 848 | [
"DDInter717",
"DDInter900"
] | Fenfluramine | Ibuprofen | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
121,
24,
848
]
],
[
[
121,
25,
1053
],
[
1053,
1,
848
]
],
[
[
121,
23,
479
],
[
479,
23,
848
]
],
[
[
121,
63,
831
],
[
831,
24... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Proca... | Fenfluramine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical e... |
DB00450 | DB00486 | 78 | 1,614 | [
"DDInter603",
"DDInter1253"
] | Droperidol | Nabilone | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
78,
24,
1614
]
],
[
[
78,
24,
530
],
[
530,
1,
1614
]
],
[
[
78,
21,
28789
],
[
28789,
60,
1614
]
],
[
[
78,
63,
999
],
[
999,
2... | [
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Droperidol (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Nabilone (Compound)
Droperidol may cause a m... |
DB01182 | DB12332 | 371 | 1,619 | [
"DDInter1534",
"DDInter1626"
] | Propafenone | Rucaparib | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
371,
24,
1619
]
],
[
[
371,
40,
271
],
[
271,
23,
1619
]
],
[
[
371,
62,
112
],
[
112,
23,
1619
]
],
[
[
371,
24,
259
],
[
259,
... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor ... | Propafenone (Compound) resembles Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Propafenone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can l... |
DB00252 | DB08865 | 362 | 1,593 | [
"DDInter1460",
"DDInter448"
] | Phenytoin | Crizotinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
362,
25,
1593
]
],
[
[
362,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
362,
7,
6952
],
[
6952,
46,
1593
]
],
[
[
362,
18,
17148
],
[
17148,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Phenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotini... | Phenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Phenytoin (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Crizotinib (Compound)
Phenytoin (Compound) downregulates ZDHHC6 (Gene) and ZDHHC6 (Gene) is downregulated by Crizotinib (Compound)
Phenytoin (Co... |
DB00912 | DB13007 | 473 | 1,060 | [
"DDInter1581",
"DDInter642"
] | Repaglinide | Enfortumab vedotin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
473,
24,
1060
]
],
[
[
473,
24,
1604
],
[
1604,
23,
1060
]
],
[
[
473,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
473,
63,
1645
],
[
1645,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib an... |
DB00344 | DB00792 | 1,302 | 832 | [
"DDInter1543",
"DDInter1878"
] | Protriptyline | Tripelennamine | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
1302,
24,
832
]
],
[
[
1302,
24,
100
],
[
100,
63,
832
]
],
[
[
1302,
24,
649
],
[
649,
1,
832
]
],
[
[
1302,
24,
1594
],
[
1594,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with C... |
DB01225 | DB05578 | 500 | 330 | [
"DDInter645",
"DDInter1566"
] | Enoxaparin | Ramucirumab | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
500,
25,
330
]
],
[
[
500,
24,
41
],
[
41,
63,
330
]
],
[
[
500,
24,
901
],
[
901,
24,
330
]
],
[
[
500,
63,
1100
],
[
1100,
24,... | [
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levo... | Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Milnacipra... |
DB00500 | DB01222 | 24 | 617 | [
"DDInter1831",
"DDInter246"
] | Tolmetin | Budesonide | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
24,
24,
617
]
],
[
[
24,
63,
251
],
[
251,
1,
617
]
],
[
[
24,
24,
175
],
[
175,
1,
617
]
],
[
[
24,
7,
3727
],
[
3727,
46,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide (Co... |
DB00939 | DB08896 | 1,338 | 292 | [
"DDInter1135",
"DDInter1576"
] | Meclofenamic acid | Regorafenib | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1338,
25,
292
]
],
[
[
1338,
21,
29276
],
[
29276,
60,
292
]
],
[
[
1338,
63,
1560
],
[
1560,
24,
292
]
],
[
[
1338,
24,
1613
],
[
161... | [
[
[
"Meclofenamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Meclofenamic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is ... | Meclofenamic acid (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Regorafenib (Compound)
Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases ... |
DB00609 | DB05773 | 595 | 1,047 | [
"DDInter694",
"DDInter1848"
] | Ethionamide | Trastuzumab emtansine | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
595,
24,
1047
]
],
[
[
595,
24,
375
],
[
375,
63,
1047
]
],
[
[
595,
24,
458
],
[
458,
24,
1047
]
],
[
[
595,
63,
147
],
[
147,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab p... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Ethionamide may cause a moderate interaction that could exacerbate diseases when tak... |
DB00358 | DB00872 | 1,010 | 1,080 | [
"DDInter1140",
"DDInter438"
] | Mefloquine | Conivaptan | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
1010,
24,
1080
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
1010,
21,
28769
],
[
28769,
60,
1080
]
],
[
[
1010,
63,
1101
],
[
1... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Mefloquine (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Conivaptan (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bexar... |
DB00586 | DB00945 | 1,512 | 1,479 | [
"DDInter537",
"DDInter20"
] | Diclofenac | Acetylsalicylic acid | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
1512,
24,
1479
]
],
[
[
1512,
40,
253
],
[
253,
40,
1479
]
],
[
[
1512,
35,
1338
],
[
1338,
24,
1479
]
],
[
[
1512,
6,
10215
],
[
1021... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Diclofenac",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} (... | Diclofenac (Compound) resembles Mefenamic acid (Compound) and Mefenamic acid (Compound) resembles Acetylsalicylic acid (Compound)
Diclofenac (Compound) resembles Meclofenamic acid (Compound) and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic... |
DB00970 | DB01030 | 0 | 869 | [
"DDInter466",
"DDInter1835"
] | Dactinomycin | Topotecan | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
0,
24,
869
]
],
[
[
0,
5,
11618
],
[
11618,
44,
869
]
],
[
[
0,
6,
17404
],
[
17404,
45,
869
]
],
[
[
0,
7,
17332
],
[
17332,
46... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Dactinomycin",
"{u} (Compound) treats {v} (Disease)",
"peripheral nervous system neoplasm"
],
[
"peripheral nervous s... | Dactinomycin (Compound) treats peripheral nervous system neoplasm (Disease) and peripheral nervous system neoplasm (Disease) is treated by Topotecan (Compound)
Dactinomycin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Topotecan (Compound)
Dactinomycin (Compound) upregulates ALDH5A1 (Gene) and ALDH5A1 (Gen... |
DB00607 | DB14723 | 1,249 | 159 | [
"DDInter1256",
"DDInter1026"
] | Nafcillin | Larotrectinib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1249,
24,
159
]
],
[
[
1249,
24,
466
],
[
466,
23,
159
]
],
[
[
1249,
24,
741
],
[
741,
24,
159
]
],
[
[
1249,
63,
597
],
[
597,
... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[... | Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nafcillin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rol... |
DB00238 | DB01234 | 188 | 1,220 | [
"DDInter1285",
"DDInter513"
] | Nevirapine | Dexamethasone | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
188,
24,
1220
]
],
[
[
188,
24,
870
],
[
870,
1,
1220
]
],
[
[
188,
24,
175
],
[
175,
40,
1220
]
],
[
[
188,
6,
6017
],
[
6017,
... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB00500 | DB00569 | 24 | 553 | [
"DDInter1831",
"DDInter775"
] | Tolmetin | Fondaparinux | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in he... | Major | 2 | [
[
[
24,
25,
553
]
],
[
[
24,
21,
28809
],
[
28809,
60,
553
]
],
[
[
24,
63,
1560
],
[
1560,
24,
553
]
],
[
[
24,
24,
222
],
[
222,
6... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compou... | Tolmetin (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Fondaparinux (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Fonda... |
DB00047 | DB00414 | 176 | 590 | [
"DDInter932",
"DDInter16"
] | Insulin glargine | Acetohexamide | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
176,
24,
590
]
],
[
[
176,
23,
1103
],
[
1103,
23,
590
]
],
[
[
176,
24,
651
],
[
651,
63,
590
]
],
[
[
176,
24,
168
],
[
168,
2... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Insulin glargine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
... | Insulin glargine may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenyto... |
DB12010 | DB12130 | 214 | 1,017 | [
"DDInter785",
"DDInter1094"
] | Fostamatinib | Lorlatinib | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
214,
24,
1017
]
],
[
[
214,
63,
608
],
[
608,
23,
1017
]
],
[
[
214,
63,
175
],
[
175,
24,
1017
]
],
[
[
214,
24,
1421
],
[
1421,
... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Tri... |
DB00196 | DB00490 | 600 | 946 | [
"DDInter743",
"DDInter254"
] | Fluconazole | Buspirone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Moderate | 1 | [
[
[
600,
24,
946
]
],
[
[
600,
6,
21998
],
[
21998,
45,
946
]
],
[
[
600,
21,
29081
],
[
29081,
60,
946
]
],
[
[
600,
24,
820
],
[
820,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
]
],
[
[
"Fluconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound ... | Fluconazole (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Buspirone (Compound)
Fluconazole (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Buspirone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00687 | DB09098 | 870 | 98 | [
"DDInter747",
"DDInter1700"
] | Fludrocortisone | Somatrem | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
870,
24,
98
]
],
[
[
870,
24,
336
],
[
336,
24,
98
]
],
[
[
870,
24,
159
],
[
159,
63,
98
]
],
[
[
870,
1,
1573
],
[
1573,
24,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib... |
DB00031 | DB09075 | 20 | 498 | [
"DDInter1764",
"DDInter621"
] | Tenecteplase | Edoxaban | Tenecteplase is a tissue plasminogen activator (tPA) developed from modifications of natural human tPA complementary DNA (cDNA). It is a 527 amino acid with a substitution of threonine 103 with asparagine and substitution of asparagine 117 with glutamine within the kringle 1 domain, and a tetra-alanine substitution at ... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
20,
25,
498
]
],
[
[
20,
23,
944
],
[
944,
62,
498
]
],
[
[
20,
24,
1004
],
[
1004,
63,
498
]
],
[
[
20,
24,
41
],
[
41,
24,
... | [
[
[
"Tenecteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phe... |
DB00712 | DB11642 | 1,274 | 938 | [
"DDInter763",
"DDInter1480"
] | Flurbiprofen | Pitolisant | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1274,
24,
938
]
],
[
[
1274,
24,
473
],
[
473,
24,
938
]
],
[
[
1274,
62,
752
],
[
752,
24,
938
]
],
[
[
1274,
63,
254
],
[
254,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Flurbiprofen may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Ci... |
DB00762 | DB00819 | 613 | 471 | [
"DDInter973",
"DDInter15"
] | Irinotecan | Acetazolamide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
613,
24,
471
]
],
[
[
613,
63,
997
],
[
997,
40,
471
]
],
[
[
613,
6,
8374
],
[
8374,
45,
471
]
],
[
[
613,
21,
28929
],
[
28929,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
],
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Irinotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Acetazolamide (Compound)
Irinotecan (Compound) causes Confusional state (Side E... |
DB00559 | DB05676 | 152 | 1,513 | [
"DDInter223",
"DDInter111"
] | Bosentan | Apremilast | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Moderate | 1 | [
[
[
152,
24,
1513
]
],
[
[
152,
24,
1040
],
[
1040,
63,
1513
]
],
[
[
152,
62,
1101
],
[
1101,
24,
1513
]
],
[
[
152,
25,
1017
],
[
1017,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene m... |
DB00585 | DB01072 | 1,127 | 915 | [
"DDInter1309",
"DDInter129"
] | Nizatidine | Atazanavir | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Major | 2 | [
[
[
1127,
25,
915
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
915
]
],
[
[
1127,
21,
28678
],
[
28678,
60,
915
]
],
[
[
1127,
63,
1031
],
[
1031... | [
[
[
"Nizatidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Atazanavir"
]
],
[
[
"Nizatidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavi... | Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Atazanavir (Compound)
Nizatidine (Compound) causes Hepatocellular injury (Side Effect) and Hepatocellular injury (Side Effect) is caused by Atazanavir (Compound)
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00046 | DB00191 | 1,179 | 73 | [
"DDInter940",
"DDInter1447"
] | Insulin lispro | Phentermine | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Moderate | 1 | [
[
[
1179,
24,
73
]
],
[
[
1179,
24,
1445
],
[
1445,
63,
73
]
],
[
[
1179,
24,
551
],
[
551,
64,
73
]
],
[
[
1179,
24,
529
],
[
529,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ph... |
DB00798 | DB01129 | 1,132 | 379 | [
"DDInter815",
"DDInter1559"
] | Gentamicin | Rabeprazole | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
1132,
24,
379
]
],
[
[
1132,
63,
1215
],
[
1215,
40,
379
]
],
[
[
1132,
63,
660
],
[
660,
1,
379
]
],
[
[
1132,
21,
29232
],
[
29232,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (... |
DB00850 | DB00889 | 1,630 | 1,133 | [
"DDInter1432",
"DDInter840"
] | Perphenazine | Granisetron | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
1630,
24,
1133
]
],
[
[
1630,
63,
19
],
[
19,
40,
1133
]
],
[
[
1630,
63,
85
],
[
85,
1,
1133
]
],
[
[
1630,
6,
8374
],
[
8374,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compou... |
DB01229 | DB12130 | 973 | 1,017 | [
"DDInter1377",
"DDInter1094"
] | Paclitaxel | Lorlatinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
973,
24,
1017
]
],
[
[
973,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
973,
25,
976
],
[
976,
24,
1017
]
],
[
[
973,
24,
1554
],
[
1554,
... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Paclitaxel may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause ... |
DB00247 | DB14723 | 1,131 | 159 | [
"DDInter1194",
"DDInter1026"
] | Methysergide | Larotrectinib | An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize sero... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1131,
24,
159
]
],
[
[
1131,
24,
222
],
[
222,
23,
159
]
],
[
[
1131,
24,
98
],
[
98,
24,
159
]
],
[
[
1131,
40,
588
],
[
588,
2... | [
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Methysergide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and S... |
DB01403 | DB09268 | 9 | 1,662 | [
"DDInter1175",
"DDInter1464"
] | Methotrimeprazine | Picosulfuric acid | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
9,
24,
1662
]
],
[
[
9,
40,
1164
],
[
1164,
24,
1662
]
],
[
[
9,
24,
484
],
[
484,
63,
1662
]
],
[
[
9,
25,
1618
],
[
1618,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
... | Methotrimeprazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a mode... |
DB00444 | DB06717 | 63 | 875 | [
"DDInter1765",
"DDInter778"
] | Teniposide | Fosaprepitant | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
63,
24,
875
]
],
[
[
63,
24,
723
],
[
723,
1,
875
]
],
[
[
63,
21,
28695
],
[
28695,
60,
875
]
],
[
[
63,
24,
351
],
[
351,
63,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Teniposide (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Fosaprepitant (Compound)
Teniposide may cause a moderate interact... |
DB00512 | DB01336 | 91 | 545 | [
"DDInter1916",
"DDInter1198"
] | Vancomycin | Metocurine | Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear. As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatm... | Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine. | Moderate | 1 | [
[
[
91,
24,
545
]
],
[
[
91,
24,
1217
],
[
1217,
40,
545
]
],
[
[
91,
24,
1441
],
[
1441,
24,
545
]
],
[
[
91,
24,
361
],
[
361,
25,... | [
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metocurine"
]
],
[
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tubocurarine"
],
[
... | Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Tubocurarine and Tubocurarine (Compound) resembles Metocurine (Compound)
Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Bacitracin and Bacitracin may cause a moderate interaction that c... |
DB00005 | DB00532 | 1,057 | 208 | [
"DDInter687",
"DDInter1152"
] | Etanercept | Mephenytoin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
1057,
24,
208
]
],
[
[
1057,
24,
608
],
[
608,
23,
208
]
],
[
[
1057,
25,
168
],
[
168,
23,
208
]
],
[
[
1057,
25,
1096
],
[
1096,
... | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Mephenytoin
Etanercept may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a m... |
DB00470 | DB00794 | 530 | 759 | [
"DDInter601",
"DDInter1521"
] | Dronabinol | Primidone | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
530,
24,
759
]
],
[
[
530,
24,
697
],
[
697,
40,
759
]
],
[
[
530,
63,
362
],
[
362,
1,
759
]
],
[
[
530,
24,
157
],
[
157,
1,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound... |
DB01064 | DB01364 | 1,148 | 22 | [
"DDInter987",
"DDInter650"
] | Isoprenaline | Ephedrine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
1148,
24,
22
]
],
[
[
1148,
63,
80
],
[
80,
24,
22
]
],
[
[
1148,
24,
1529
],
[
1529,
63,
22
]
],
[
[
1148,
24,
280
],
[
280,
1,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine an... |
DB01068 | DB12010 | 1,565 | 214 | [
"DDInter411",
"DDInter785"
] | Clonazepam | Fostamatinib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1565,
24,
214
]
],
[
[
1565,
63,
723
],
[
723,
24,
214
]
],
[
[
1565,
24,
1478
],
[
1478,
24,
214
]
],
[
[
1565,
62,
1031
],
[
1031,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivaca... |
DB00400 | DB08899 | 353 | 129 | [
"DDInter843",
"DDInter649"
] | Griseofulvin | Enzalutamide | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
353,
24,
129
]
],
[
[
353,
6,
8374
],
[
8374,
45,
129
]
],
[
[
353,
21,
28921
],
[
28921,
60,
129
]
],
[
[
353,
23,
271
],
[
271,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Griseofulvin (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Mirabegron ... |
DB01156 | DB08865 | 593 | 1,593 | [
"DDInter252",
"DDInter448"
] | Bupropion | Crizotinib | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
593,
24,
1593
]
],
[
[
593,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
593,
7,
7972
],
[
7972,
46,
1593
]
],
[
[
593,
18,
9385
],
[
9385,
... | [
[
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Bupropion",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bupropion (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Bupropion (Compound) upregulates COL11A1 (Gene) and COL11A1 (Gene) is upregulated by Crizotinib (Compound)
Bupropion (Compound) downregulates MRPL19 (Gene) and MRPL19 (Gene) is upregulated by Crizotinib (Compound)
Bupropion (Co... |
DB00405 | DB00771 | 128 | 262 | [
"DDInter517",
"DDInter397"
] | Dexbrompheniramine | Clidinium | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
128,
24,
262
]
],
[
[
128,
24,
1511
],
[
1511,
63,
262
]
],
[
[
128,
24,
1688
],
[
1688,
1,
262
]
],
[
[
128,
24,
19
],
[
19,
24... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diph... |
DB00001 | DB03404 | 1,578 | 765 | [
"DDInter1037",
"DDInter855"
] | Lepirudin | Hemin | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence o... | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
1578,
24,
765
]
],
[
[
1578,
25,
840
],
[
840,
63,
765
]
],
[
[
1578,
25,
1018
],
[
1018,
24,
765
]
],
[
[
1578,
24,
1061
],
[
1061,
... | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
],
[
"Vorapaxar",
... | Lepirudin may lead to a major life threatening interaction when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Lepirudin may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction... |
DB01178 | DB01233 | 369 | 1,311 | [
"DDInter357",
"DDInter1197"
] | Chlormezanone | Metoclopramide | A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
369,
24,
1311
]
],
[
[
369,
63,
662
],
[
662,
24,
1311
]
],
[
[
369,
24,
1532
],
[
1532,
24,
1311
]
],
[
[
369,
24,
407
],
[
407,
... | [
[
[
"Chlormezanone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Chlormezanone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
... | Chlormezanone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide
Chlormezanone may cause a moderate interaction that could exacerbate diseases when taken with Ifosf... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.